PMDD announced demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when examined in an extended 9-day analysis of symptom reduction. Senior PMDD Key Opinion Leaders who co-authored the publication include Dr. Nick Panay (Imperial College London), Prof. Shaughn O'Brien (Royal Stoke University Hospital, UK), Prof. C. Neill Epperson (Dept. Psychiatry, University of Colorado), Prof Marie Bixo (Umeå University, Sweden) and Dr. Angelica Lindén Hirschberg, Karolinska University Hospital, Stockholm, Sweden ­ together with Asarina Pharma CSO Prof Torbjörn Bäckström (Umeå University, Sweden). Topline results for Asarina Pharma's phase IIb study in Sepranolone for PMDD, released in April 2020, found that Sepranolone failed to meet its primary or secondary clinical endpoints in its 5-day targeted treatment period of the five worst premenstrual days, due to an unexpectedly high placebo effect. A post hoc analysis was undertaken to investigate the treatment effect during an extended 9 premenstrual days in the third treatment cycle (it has previously been shown that 9 premenstrual days may be more representative for comparison of PMDD symptom periods than the 5 worst premenstrual days).